There are 2867 resources available
1477P - Molecular epidemiology of somatic VHL alterations in Chinese patients with solid tumors
Presenter: Haojie Zhang
Session: Poster session 17
1478P - Clearseq1-4 classifier in localized and metastatic clear-cell renal cell carcinoma (ccRCC)
Presenter: Lisa Kinget
Session: Poster session 17
1479P - Ultra-sensitive circulating tumor DNA (ctDNA) assay distinguishes partial response (PR) and complete response (CR) with immunotherapy in metastatic renal cell carcinoma (mRCC)
Presenter: Alexander Chehrazi-Raffle
Session: Poster session 17
1481TiP - A prospective, randomized phase II trial of neoadjuvant immunotherapy in primary clear cell renal cancer at risk for recurrence or distant metastases: The NESCIO trial
Presenter: Femke Burgers
Session: Poster session 17
1738P - Three-year follow-up update and survival outcomes of the PURE-01 study
Presenter: Tiago Padua
Session: Poster session 17
1739P - Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: Analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502)
Presenter: Andrew Weickhardt
Session: Poster session 17
1740P - Bladder preservation therapy in combination with atezolizumab and radiation therapy for invasive bladder cancer (BPT-ART): An open-label, single-arm, multicenter, phase II trial
Presenter: Yoshiyuki Nagumo
Session: Poster session 17
1741P - Atezolizumab (ATZ) with split-doses of cisplatin plus gemcitabine in patients with locally advanced or metastatic urothelial carcinoma (SOGUG-AUREA): A multicentre, single-arm phase II trial
Presenter: Guillermo Antonio De Velasco Oria
Session: Poster session 17
1742P - Phase II study of rucaparib and atezolizumab (ARIANES): Results in patients (pts) with platinum-sensitive metastatic urothelial cancer (mUC) and metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Patricia Martin Romano
Session: Poster session 17